Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04467931 · ClinicalTrials.gov registry record
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
A clinical trial of Hypertension and COVID, sponsored by University of Utah.
- Completed
- Registry status
- 22,213
- Enrollment target
- 1
- Study location
NCT04467931: Completed study of Hypertension and COVID, sponsored by University of Utah.
NCT04467931 is a study of Hypertension and COVID that has completed, run by University of Utah. The registered enrollment target is 22,213 participants, above the 3,460-participant average among 470 other Hypertension trials with a reported enrollment target (542% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04467931, a study of Hypertension and COVID, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- 22,213 participants
- Enrollment target
- 1
- Study location
Study Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase, decrease, or have no significant effect on ACE2 expression or activity. Therefore, ACEI and ARB may be harmful, beneficial, or have no impact on Coronavirus Disease 2019 severity and mortality. The Specific Aims of this observational study are: (1) Among SARS-CoV-2-positive outpatients, compare all-cause hospitalization and mortality rates between: 1.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 1.2 Current users of a range of doses of ACEI- vs. ARB-based regimens, and (2) Among those hospitalized for COVID-19, compare all-cause mortality between: 2.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 2.2 Current users of a range of doses of ACEI- vs. ARB-based regimens.
Primary Outcome
For outpatient Veterans with a positive SARS-CoV-2 test (Aims 1.1 and 1.2), the primary outcome is a composite of time to all-cause hospitalization or all-cause mortality.
Conditions Studied
Interventions
- DRUG ACEI/ARB
- DRUG Non-ACEI/ARB
- DRUG ACEI
- DRUG ARB
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,213 participants |
| Start Date | 2020-01-19 |
| Est. Completion | 2020-12-31 |
What the finished NCT04467931 record still lists
NCT04467931 is an observational study that tracks outcomes without assigning an intervention. Its 22,213 participants enrollment target places it among the larger protocols in the corpus, above the 3,460-participant average among 470 other Hypertension trials with a reported enrollment target (542% higher).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which ACEI/ARB is the first listed.
NCT04467931 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04467931 about?
NCT04467931 is a clinical study titled "ACEI or ARB and COVID-19 Severity and Mortality in US Veterans". Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase, decrease, or have no significant ...
What is the current status of trial NCT04467931?
This trial is currently completed. The enrollment target is 22,213 participants. The study started on 2020-01-19. Estimated completion is 2020-12-31.
What conditions does trial NCT04467931 study?
This clinical trial studies the following conditions: Hypertension, COVID.
What interventions are being tested in trial NCT04467931?
The interventions under investigation include: ACEI/ARB (DRUG), Non-ACEI/ARB (DRUG), ACEI (DRUG), ARB (DRUG).
Who is sponsoring clinical trial NCT04467931?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04467931 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04467931's enrollment target sits among peer trials
22,213 12th of 470 higher than 459 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Childhood-Onset Essential Hypertension Natural History Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06486688 · 22,320 participants · NA
Centralized Virtual SBIRT for Pediatric Primary Care
- NCT07413211 · 22,068 participants
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI